All Stories

  1. Regulation of FGF23 Production in Osteocytes

    Article • Current Osteoporosis Reports, February 2024, Springer Science + Business Media

    Seiji Fukumoto

  2. Tumor-induced osteomalacia

    Article • Panminerva Medica, December 2023, Edizioni Minerva Medica

    Seiji Fukumoto

  3. Special Issue: “X-Linked Hypophosphatemia”

    Article • Endocrines, November 2023, MDPI AG

    Seiji Fukumoto

  4. Recent basic and clinical findings concerning FGF23: A bone-derived hormone

    Article • Current Opinion in Endocrine and Metabolic Research, April 2023, Elsevier

    Seiji Fukumoto

  5. Effect of Conventional Treatment on Dental Complications and Ectopic Ossifications Among 30 Adults With XLH

    Article • The Journal of Clinical Endocrinology & Metabolism, December 2022, Endocrine Society

    Seiji Fukumoto

  6. Etiology and Pathophysiology of Hypoparathyroidism: A Narrative Review

    Article • Journal of Bone and Mineral Research, November 2022, Wiley

    Seiji Fukumoto

  7. Tumor-induced Osteomalacia: A Comprehensive Review

    Article • Endocrine Reviews, November 2022, Endocrine Society

    Seiji Fukumoto

  8. FGF23 and Hypophosphatemic Rickets/Osteomalacia

    Article • Current Osteoporosis Reports, November 2021, Springer Science + Business Media

    Seiji Fukumoto

  9. Skeletal FGFR1 signaling is necessary for regulation of serum phosphate level by FGF23 and normal life span

    Article • Biochemistry and Biophysics Reports, September 2021, Elsevier

    Seiji Fukumoto

  10. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment

    Article • Journal of Molecular Endocrinology, February 2021, Bioscientifica

    Seiji Fukumoto

  11. Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR

    Article • Journal of Bone and Mineral Metabolism, February 2020, Springer Science + Business Media

    Seiji Fukumoto

  12. Fibroblast growth factor 23

    Article • January 2020, Elsevier

    Seiji Fukumoto

  13. How do we sense phosphate to regulate serum phosphate level?

    Article • Journal of Bone and Mineral Metabolism, December 2019, Springer Science + Business Media

    Seiji Fukumoto

  14. FGF23-related hypophosphatemic diseases: prospect for new treatment

    Article • Endocrine Abstracts, November 2019, Bioscientifica

    Seiji Fukumoto

  15. Earlier Onset in Autosomal Dominant Hypophosphatemic Rickets of R179 than R176 Mutations in Fibroblast Growth Factor 23: Report of 20 Chinese Cases and Review of the Literature

    Article • Calcified Tissue International, September 2019, Springer Science + Business Media

    Seiji Fukumoto

  16. Circulating FGF23 is not associated with cardiac dysfunction, atherosclerosis, infection or inflammation in hemodialysis patients

    Article • Journal of Bone and Mineral Metabolism, August 2019, Springer Science + Business Media

    Seiji Fukumoto

  17. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases

    Article • EBioMedicine, July 2019, Elsevier

    Seiji Fukumoto

  18. Ectopic expression of Klotho in fibroblast growth factor 23 (FGF23)-producing tumors that cause tumor-induced rickets/osteomalacia (TIO)

    Article • Bone Reports, June 2019, Elsevier

    Seiji Fukumoto

  19. Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation

    Article • Proceedings of the National Academy of Sciences, May 2019, Proceedings of the National Academy of Sciences

    Seiji Fukumoto

  20. Phosphate Metabolism, Hyperphosphatemia, and Hypophosphatemia

    Article • January 2019, Elsevier

    Seiji Fukumoto

  21. FGF23 and Bone and Mineral Metabolism

    Article • January 2019, Springer Science + Business Media

    Seiji Fukumoto

  22. FGF23 beyond Phosphotropic Hormone

    Article • Trends in Endocrinology and Metabolism, November 2018, Elsevier

    Seiji Fukumoto

  23. Targeting Fibroblast Growth Factor 23 Signaling with Antibodies and Inhibitors, Is There a Rationale?

    Article • Frontiers in Endocrinology, February 2018, Frontiers

    Seiji Fukumoto

  24. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment

    Article • Endocrine Reviews, January 2018, Endocrine Society

    Seiji Fukumoto

  25. Development of versatile non-homologous end joining-based knock-in module for genome editing

    Article • Scientific Reports, January 2018, Springer Science + Business Media

    Seiji Fukumoto

  26. Incidence rate and characteristics of symptomatic vitamin D deficiency in children: a nationwide survey in Japan

    Article • Endocrine Journal, January 2018, Japan Endocrine Society

    Dr Kosei Hasegawa, Seiji Fukumoto

  27. Prevalence and clinical outcomes of hip fractures and subchondral insufficiency fractures of the femoral head in patients with tumour-induced osteomalacia

    Article • International Orthopaedics, August 2017, Springer Science + Business Media

    Seiji Fukumoto

  28. Enpp1 is an anti-aging factor that regulates Klotho under phosphate overload conditions

    Article • Scientific Reports, August 2017, Springer Science + Business Media

    Seiji Fukumoto

  29. Tumour-induced osteomalacia

    Article • Nature Reviews Disease Primers, July 2017, Springer Science + Business Media

    Seiji Fukumoto

  30. Recent advances in the management of osteoporosis

    Article • F1000Research, May 2017, Faculty of 1000, Ltd.

    Seiji Fukumoto, Toshio Matsumoto

  31. Changes in bone metabolic parameters following oral calcium supplementation in an adult patient with vitamin D-dependent rickets type 2A

    Article • Endocrine Journal, January 2017, Japan Endocrine Society

    Seiji Fukumoto

  32. Tumor-induced Osteomalacia Caused by a Parotid Tumor

    Article • Internal Medicine, January 2017, Japanese Society of Internal Medicine

    Seiji Fukumoto

  33. Three-dimensional fluoroscopic navigation-assisted surgery for tumors in patients with tumor-induced osteomalacia in the bones

    Article • Computer Assisted Surgery, January 2017, Taylor & Francis

    Seiji Fukumoto

  34. Assessment criteria for vitamin D deficiency/insufficiency in Japan — proposal by an expert panel supported by Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral ...

    Article • Endocrine Journal, January 2017, Japan Endocrine Society

    Seiji Fukumoto

  35. Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23

    Article • Endocrine Journal, January 2017, Japan Endocrine Society

    Seiji Fukumoto

  36. Remarkable Shrinkage of a Growth Hormone (GH)-secreting Macroadenoma Induced by Somatostatin Analogue Administration: A Case Report and Literature Review

    Article • Internal Medicine, January 2017, Japanese Society of Internal Medicine

    Seiji Fukumoto

  37. Assessment criteria for vitamin D deficiency/insufficiency in Japan: proposal by an expert panel supported by the Research Program of Intractable Diseases, Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Researc...

    Article • Journal of Bone and Mineral Metabolism, November 2016, Springer Science + Business Media

    Seiji Fukumoto

  38. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy

    Article • Endocrine Research, October 2016, Taylor & Francis

    Seiji Fukumoto

  39. FGF23-Klotho axis in CKD

    Article • Renal Replacement Therapy, May 2016, Springer Science + Business Media

    Seiji Fukumoto

  40. High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors

    Article • Endocrine Journal, January 2016, Japan Endocrine Society

    Seiji Fukumoto

  41. Serum carboxy-terminal telopeptide of type I collagen levels are associated with carotid atherosclerosis in patients with cardiovascular risk factors

    Article • Endocrine Journal, January 2016, Japan Endocrine Society

    Seiji Fukumoto

  42. Suppression of the Hypothalamic-pituitary-adrenal Axis by Maximum Androgen Blockade in a Patient with Prostate Cancer

    Article • Internal Medicine, January 2016, Japanese Society of Internal Medicine

    Seiji Fukumoto

  43. Pathogenesis and diagnostic criteria for rickets and osteomalacia—proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society

    Article • Journal of Bone and Mineral Metabolism, July 2015, Springer Science + Business Media

    Seiji Fukumoto

  44. Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH)

    Article • Journal of Bone and Mineral Research, July 2015, Wiley

    Seiji Fukumoto

  45. FGF23-FGF Receptor/Klotho Pathway as a New Drug Target for Disorders of Bone and Mineral Metabolism

    Article • Calcified Tissue International, July 2015, Springer Science + Business Media

    Seiji Fukumoto

  46. ERG and FLI1 are useful immunohistochemical markers in phosphaturic mesenchymal tumors

    Article • Medical Molecular Morphology, June 2015, Springer Science + Business Media

    Seiji Fukumoto

  47. Oncogenic osteomalacia caused by an occult paranasal sinus tumor

    Article • Auris Nasus Larynx, April 2015, Elsevier

    Seiji Fukumoto

  48. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells

    Article • Journal of Bone and Mineral Metabolism, March 2015, Springer Science + Business Media

    Seiji Fukumoto

  49. Rapid Recovery of Hypothalamic-Pituitary Axis after Successful Resection of an ACTH-secreting Neuroendocrine Tumor

    Article • Internal Medicine, January 2015, Japanese Society of Internal Medicine

    Seiji Fukumoto

  50. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment

    Article • Endocrine Journal, January 2015, Japan Endocrine Society

    Seiji Fukumoto

  51. Pathogenesis and diagnostic criteria for rickets and osteomalacia — Proposal by an expert panel supported by Ministry of Health, Labour and Welfare, Japan, The Japanese Society for Bone and Mineral Research and The Japan Endocrine Society [Opinion]

    Article • Endocrine Journal, January 2015, Japan Endocrine Society

    Seiji Fukumoto

  52. Tumor-induced osteomalacia caused by phosphaturic mesenchymal tumor of the cervical spine

    Article • Journal of Orthopaedic Science, January 2015, Elsevier

    Seiji Fukumoto

  53. Hypophosphatemic osteomalacia and bone sclerosis caused by a novel homozygous mutation of the FAM20C gene in an elderly man with a mild variant of Raine syndrome

    Article • Bone, October 2014, Elsevier

    Dr Kosei Hasegawa, Seiji Fukumoto

  54. Functional analysis of mutant FAM20C in Raine syndrome with FGF23-related hypophosphatemia

    Article • Bone, October 2014, Elsevier

    Seiji Fukumoto

  55. What can FGF23 do without Klotho?

    Article • BoneKEy Reports, July 2014, Portico

    Seiji Fukumoto

  56. Anti-fibroblast growth factor 23 antibody therapy

    Article • Current Opinion in Nephrology & Hypertension, July 2014, Wolters Kluwer Health

    Seiji Fukumoto

  57. Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency

    Article • Kidney International, May 2014, Elsevier

    Seiji Fukumoto

  58. Phosphate metabolism and vitamin D

    Article • BoneKEy Reports, February 2014, Portico

    Seiji Fukumoto

  59. Functional Activities of Mutant Calcium-Sensing Receptors Determine Clinical Presentations in Patients With Autosomal Dominant Hypocalcemia

    Article • The Journal of Clinical Endocrinology & Metabolism, February 2014, Endocrine Society

    Seiji Fukumoto

  60. Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia

    Article • Endocrinology and Metabolism, January 2014, Korean Endocrine Society (KAMJE)

    Seiji Fukumoto

  61. Phosphate enhances reactive oxygen species production and suppresses osteoblastic differentiation

    Article • Journal of Bone and Mineral Metabolism, September 2013, Springer Science + Business Media

    Seiji Fukumoto

  62. Clinical Practice Guideline for the Management of Chronic Kidney Disease-Mineral and Bone Disorder

    Article • Therapeutic Apheresis and Dialysis, June 2013, Wiley

    Hideki Fujii, Dr Hirotaka Komaba, Seiji Fukumoto

  63. Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2013, Endocrine Society

    Natalie A Sims, Kate Vandyke, Seiji Fukumoto

  64. Clinical Aspects of Fibroblast Growth Factor 23

    Article • January 2013, Elsevier

    Seiji Fukumoto

  65. A Case of Bardet-Biedl Syndrome with a Pituitary Tumor and Growth Hormone Deficiency

    Article • Nihon Naika Gakkai Zasshi, January 2013, Japanese Society of Internal Medicine

    Seiji Fukumoto

  66. 952 FIBROBLAST GROWTH FACTOR 23 ACCELERATES PHOSPHATE-INDUCED CALCIFICATION OF VASCULAR SMOOTH MUSCLE CELLS

    Article • Journal of Hypertension, September 2012, Wolters Kluwer Health

    Seiji Fukumoto

  67. What's new in FGF23 research?

    Article • BoneKEy Reports, July 2012, Portico

    Seiji Fukumoto

  68. Kidney transplantation restored uncoupled bone turnover in end-stage renal disease

    Article • Clinical Nephrology, July 2012, Dustri-Verlgag Dr. Karl Feistle

    Seiji Fukumoto

  69. Mutational analysis of patients with FGF23-related hypophosphatemic rickets

    Article • May 2012, Bioscientifica

    Seiji Fukumoto

  70. FGF23 as a Novel Therapeutic Target

    Article • January 2012, Springer Science + Business Media

    Seiji Fukumoto

  71. Fibroblast Growth Factor 23-Related Osteomalacia Caused by the Prolonged Administration of Saccharated Ferric Oxide

    Article • Internal Medicine, January 2012, Japanese Society of Internal Medicine

    Seiji Fukumoto

  72. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene

    Article • Bone, October 2011, Elsevier

    Seiji Fukumoto

  73. Evaluation of a new automated chemiluminescence immunoassay for FGF23

    Article • Journal of Bone and Mineral Metabolism, September 2011, Springer Science + Business Media

    Seiji Fukumoto

  74. Fibroblast growth factor 23 as a phosphotropic hormone and beyond

    Article • Journal of Bone and Mineral Metabolism, August 2011, Springer Science + Business Media

    Seiji Fukumoto

  75. Hypoxia signaling: Meeting report from the 3rd joint meeting of the European Calcified Tissue Society and the International Bone and Mineral Society

    Article • IBMS BoneKEy, August 2011, Nature

    Seiji Fukumoto

  76. Natural History of Mineral and Bone Disorders After Living-Donor Kidney Transplantation: A One-Year Prospective Observational Study

    Article • Therapeutic Apheresis and Dialysis, May 2011, Wiley

    Seiji Fukumoto

  77. Osteomalacia Caused by Skull Base Tumors: Report of 2 Cases

    Article • Neurosurgery, March 2011, Oxford University Press (OUP)

    Professor Kensuke Kawai, Seiji Fukumoto

  78. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice

    Article • Journal of Bone and Mineral Research, March 2011, Wiley

    Seiji Fukumoto

  79. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study

    Article • Nephrology Dialysis Transplantation, February 2011, Oxford University Press (OUP)

    Seiji Fukumoto

  80. Minireview: Fibroblast Growth Factor 23 in Phosphate Homeostasis and Bone Metabolism

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2011, Endocrine Society

    Seiji Fukumoto

  81. Minireview: Fibroblast Growth Factor 23 in Phosphate Homeostasis and Bone Metabolism

    Article • Endocrinology, January 2011, Endocrine Society

    Seiji Fukumoto

  82. A Case of FGF23-related Hypophosphatemic Osteomalacia Caused by Long-term Administration of Saccharated Ferric Oxide.

    Article • Nihon Naika Gakkai Zasshi, January 2011, Japanese Society of Internal Medicine

    Seiji Fukumoto

  83. Physiological and Pathophygiological Significance of a Phosphotropic Hormone, FGF23.

    Article • Nihon Naika Gakkai Zasshi, January 2011, Japanese Society of Internal Medicine

    Seiji Fukumoto

  84. Phosphate metabolism: Meeting report from the 32nd annual meeting of the American Society for bone and mineral research October 15-19, 2010 in Toronto, Ontario, Canada

    Article • IBMS BoneKEy, December 2010, Nature

    Seiji Fukumoto

  85. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease

    Article • Kidney International, November 2010, Elsevier

    Seiji Fukumoto

  86. FGF23: Phosphate metabolism and beyond

    Article • IBMS BoneKEy, August 2010, Nature

    Seiji Fukumoto

  87. Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia

    Article • Journal of Internal Medicine, July 2010, Wiley

    Seiji Fukumoto

  88. Runx1 and Runx2 cooperate during sternal morphogenesis

    Article • Development, April 2010, The Company of Biologists

    Koji Fujita, Seiji Fukumoto

  89. Tumor-induced osteomalacia associated with a maxillofacial tumor producing fibroblast growth factor 23: report of a case and review of the literature

    Article • Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, March 2010, Elsevier

    Seiji Fukumoto

  90. Long-term clinical course of IgG4-related systemic disease accompanied by hypophysitis

    Article • Endocrine Journal, January 2010, Japan Endocrine Society

    Seiji Fukumoto

  91. A microRNA regulatory mechanism of osteoblast differentiation

    Article • Proceedings of the National Academy of Sciences, December 2009, Proceedings of the National Academy of Sciences

    Koji Fujita, Seiji Fukumoto

  92. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia*

    Article • Journal of Bone and Mineral Research, November 2009, Wiley

    Seiji Fukumoto

  93. The role of bone in phosphate metabolism

    Article • Molecular and Cellular Endocrinology, October 2009, Elsevier

    Seiji Fukumoto

  94. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide

    Article • Bone, October 2009, Elsevier

    Seiji Fukumoto

  95. Familial hypophosphatemic rickets caused by a large deletion in PHEX gene

    Article • European Journal of Endocrinology, October 2009, Oxford University Press (OUP)

    Seiji Fukumoto

  96. Bone as an endocrine organ

    Article • Trends in Endocrinology and Metabolism, July 2009, Elsevier

    Seiji Fukumoto

  97. Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism

    Article • International Journal of Pediatric Endocrinology, January 2009, Springer Science + Business Media

    Seiji Fukumoto

  98. Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism

    Article • International Journal of Pediatric Endocrinology, January 2009, Springer Science + Business Media

    Seiji Fukumoto

  99. A novel mutation in the GATA3 gene of a Japanese patient with PTH-deficient hypoparathyroidism

    Article • Journal of Bone and Mineral Metabolism, December 2008, Springer Science + Business Media

    Seiji Fukumoto

  100. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients

    Article • Bone, June 2008, Elsevier

    Seiji Fukumoto

  101. Anti-FGF23 Neutralizing Antibodies Show the Physiological Role and Structural Features of FGF23

    Article • Journal of Bone and Mineral Research, April 2008, Wiley

    Seiji Fukumoto

  102. Actions and Mode of Actions of FGF19 Subfamily Members

    Article • Endocrine Journal, January 2008, Japan Endocrine Society

    Seiji Fukumoto

  103. 4. Treatment of Secondary Osteoporoses

    Article • Nihon Naika Gakkai Zasshi, January 2008, Japanese Society of Internal Medicine

    Seiji Fukumoto

  104. Physiological Regulation and Disorders of Phosphate Metabolism -Pivotal Role of Fibroblast Growth Factor 23-

    Article • Internal Medicine, January 2008, Japanese Society of Internal Medicine

    Seiji Fukumoto

  105. Development of Tumor-induced Osteomalacia in a Subcutaneous Tumor, Defined by Venous Blood Sampling of Fibroblast Growth Factor-23

    Article • Internal Medicine, January 2008, Japanese Society of Internal Medicine

    Seiji Fukumoto

  106. Tumor-Induced Hypophosphatemic Osteomalacia Diagnosed by the Combinatory Procedures of Magnetic Resonance Imaging and Venous Sampling for FGF23

    Article • Internal Medicine, January 2008, Japanese Society of Internal Medicine

    Seiji Fukumoto

  107. Causes and Differential Diagnosis of Hypocalcemia —Recommendation Proposed by Expert Panel Supported by Ministry of Health, Labour and Welfare, Japan—

    Article • Endocrine Journal, January 2008, Japan Endocrine Society

    Seiji Fukumoto

  108. Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans

    Article • Journal of Bone and Mineral Metabolism, October 2007, Springer Science + Business Media

    Seiji Fukumoto

  109. Persistent high level of fibroblast growth factor 23 as a cause of post-renal transplant hypophosphatemia

    Article • Clinical and Experimental Nephrology, September 2007, Springer Science + Business Media

    Seiji Fukumoto

  110. Central control of bone remodeling by neuromedin U

    Article • Nature Reports Stem Cells, September 2007, Nature

    Seiji Fukumoto

  111. FGF23 is a hormone-regulating phosphate metabolism—Unique biological characteristics of FGF23

    Article • Bone, May 2007, Elsevier

    Seiji Fukumoto

  112. 3. Tumor-induced Hypophosphatemic Osteomalacia

    Article • Nihon Naika Gakkai Zasshi, January 2007, Japanese Society of Internal Medicine

    Seiji Fukumoto

  113. Fibroblast Growth Factor (FGF)23 in Patients with Acromegaly

    Article • Endocrine Journal, January 2007, Japan Endocrine Society

    Seiji Fukumoto

  114. 1. Regulation of Phosphorus-Vitamin D Metabolism by Fibroblast Growth Factor (FGF) 23

    Article • Nihon Naika Gakkai Zasshi, January 2007, Japanese Society of Internal Medicine

    Seiji Fukumoto

  115. Fibroblast Growth Factor-23 (FGF23) in Patients with Transient Hypoparathyroidism: Its Important Role in Serum Phosphate Regulation

    Article • Endocrine Journal, January 2007, Japan Endocrine Society

    Seiji Fukumoto

  116. Hyperostosis-Hyperphosphatemia Syndrome: A Congenital Disorder of O-Glycosylation Associated With Augmented Processing of Fibroblast Growth Factor 23

    Article • Journal of Bone and Mineral Research, November 2006, Wiley

    Seiji Fukumoto

  117. Klotho converts canonical FGF receptor into a specific receptor for FGF23

    Article • Nature, October 2006, Springer Science + Business Media

    Seiji Fukumoto

  118. An Instructive Case Suggesting Cyclical Primary Hyperparathyroidism

    Article • Endocrine Journal, January 2006, Japan Endocrine Society

    Seiji Fukumoto

  119. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways

    Article • Journal of Cellular Biochemistry, January 2006, Wiley

    Seiji Fukumoto

  120. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism

    Article • AJP Renal Physiology, November 2005, American Physiological Society

    Seiji Fukumoto

  121. Comparison of two assays for fibroblast growth factor (FGF)-23

    Article • Journal of Bone and Mineral Metabolism, October 2005, Springer Science + Business Media

    Seiji Fukumoto

  122. A Novel Mutation in Fibroblast Growth Factor 23 Gene as a Cause of Tumoral Calcinosis

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2005, Endocrine Society

    Seiji Fukumoto

  123. Post-translational Modification of Fibroblast Growth Factor 23

    Article • Therapeutic Apheresis and Dialysis, August 2005, Wiley

    Seiji Fukumoto

  124. Fibroblast Growth Factor-23 in Patients with Graves’ Disease before and after Antithyroid Therapy: Its Important Role in Serum Phosphate Regulation

    Article • The Journal of Clinical Endocrinology & Metabolism, July 2005, Endocrine Society

    Seiji Fukumoto

  125. Intravenous Calcitriol Therapy Increases Serum Concentrations of Fibroblast Growth Factor-23 in Dialysis Patients with Secondary Hyperparathyroidism

    Article • Nephron Clinical Practice, June 2005, Karger Publishers

    Seiji Fukumoto

  126. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients

    Article • Kidney International, March 2005, Elsevier

    Seiji Fukumoto

  127. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients

    Article • Kidney International, March 2005, Elsevier

    Seiji Fukumoto

  128. 骨粗しょう症：診断と治療の進歩　　Ｖ．骨粗しょう症をとりまく新たな展開　　２．副甲状腺ホルモン（ｐａｒａｔｈｙｒｏｉｄ　ｈｏｒｍｏｎｅ：ＰＴＨ）

    Article • Nihon Naika Gakkai Zasshi, January 2005, Japanese Society of Internal Medicine

    Seiji Fukumoto

  129. Ghrelin Directly Regulates Bone Formation

    Article • Journal of Bone and Mineral Research, December 2004, Wiley

    Seiji Fukumoto

  130. Venous Sampling for Fibroblast Growth Factor-23 Confirms Preoperative Diagnosis of Tumor-Induced Osteomalacia

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2004, Endocrine Society

    Seiji Fukumoto

  131. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency

    Article • American Journal of Kidney Diseases, August 2004, Elsevier

    Seiji Fukumoto

  132. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

    Article • Journal of Clinical Investigation, February 2004, American Society for Clinical Investigation

    Seiji Fukumoto

  133. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism

    Article • Journal of Clinical Investigation, February 2004, American Society for Clinical Investigation

    Seiji Fukumoto

  134. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa

    Article • Biochemical and Biophysical Research Communications, February 2004, Elsevier

    Seiji Fukumoto

  135. リン代謝異常症とＦＧＦ－２３

    Article • Nihon Naika Gakkai Zasshi, January 2004, Japanese Society of Internal Medicine

    Seiji Fukumoto

  136. FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis

    Article • Journal of Bone and Mineral Research, December 2003, Wiley

    Seiji Fukumoto

  137. Decreased AP-1 Activity and Interleukin-11 Expression by Bone Marrow Stromal Cells May Be Associated With Impaired Bone Formation in Aged Mice

    Article • Journal of Bone and Mineral Research, August 2003, Wiley

    Seiji Fukumoto

  138. Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, July 2003, New England Journal of Medicine (NEJM/MMS)

    Seiji Fukumoto

  139. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients

    Article • Journal of Bone and Mineral Metabolism, May 2003, Springer Science + Business Media

    Seiji Fukumoto

  140. Receptor Tyrosine Kinases Inhibit Bone Morphogenetic Protein-Smad Responsive Promoter Activity and Differentiation of Murine MC3T3-E1 Osteoblast-like Cells

    Article • Journal of Bone and Mineral Research, May 2003, Wiley

    Seiji Fukumoto

  141. A Family of Autosomal Dominant Hypocalcemia with an Activating Mutation of Calcium-Sensing Receptor Gene.

    Article • Endocrine Journal, January 2003, Japan Endocrine Society

    Seiji Fukumoto

  142. Interleukin-11 as a Stimulatory Factor for Bone Formation Prevents Bone Loss with Advancing Age in Mice

    Article • Journal of Biological Chemistry, December 2002, Elsevier

    Seiji Fukumoto

  143. Increased Circulatory Level of Biologically Active Full-Length FGF-23 in Patients with Hypophosphatemic Rickets/Osteomalacia

    Article • The Journal of Clinical Endocrinology & Metabolism, November 2002, Endocrine Society

    Seiji Fukumoto

  144. Association between activating mutations of calcium-sensing receptor and Bartter's syndrome

    Article • The Lancet, August 2002, Elsevier

    Seiji Fukumoto

  145. Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemiain Vivo

    Article • Endocrinology, August 2002, Endocrine Society

    Seiji Fukumoto

  146. Mutant FGF-23 Responsible for Autosomal Dominant Hypophosphatemic Rickets Is Resistant to Proteolytic Cleavage and Causes Hypophosphatemia in Vivo

    Article • Endocrinology, August 2002, Endocrine Society

    Seiji Fukumoto

  147. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin

    Article • Current Opinion in Nephrology & Hypertension, July 2002, Wolters Kluwer Health

    Seiji Fukumoto

  148. A Family of Autosomal Dominant Hypocalcemia with a Positive Correlation between Serum Calcium and Magnesium: Identification of a Novel Gain of Function Mutation (Ser820Phe) in the Calcium-Sensing Receptor

    Article • The Journal of Clinical Endocrinology & Metabolism, June 2002, Endocrine Society

    Seiji Fukumoto

  149. Parathyroid Hormone-Related Protein Induced Coupled Increases in Bone Formation and Resorption Markers for 7 Years in a Patient With Malignant Islet Cell Tumors

    Article • Journal of Bone and Mineral Research, May 2002, Wiley

    Seiji Fukumoto

  150. Stimulation of Smad1 Transcriptional Activity by Ras-Extracellular Signal-Regulated Kinase Pathway: A Possible Mechanism for Collagen-Dependent Osteoblastic Differentiation

    Article • Journal of Bone and Mineral Research, February 2002, Wiley

    Seiji Fukumoto

  151. Clonal Endothelial Cells Produce Humoral Factors that Inhibit Osteoclast-Like Cell Formation In Vitro.

    Article • Endocrine Journal, January 2002, Japan Endocrine Society

    Seiji Fukumoto

  152. Marked Hypercalcemia in a Patient with Hypocalciuric Hypercalcemia without a Mutation in the Calcium-Sensing Receptor Gene.

    Article • Internal Medicine, January 2002, Japanese Society of Internal Medicine

    Seiji Fukumoto

  153. Inactivating Mutations of Calcium-Sensing Receptor Results in Parathyroid Lipohyperplasia

    Article • Diagnostic Molecular Pathology, December 2001, Wolters Kluwer Health

    Seiji Fukumoto

  154. Focal Adhesion Kinase Activity Is Required for Bone Morphogenetic Protein-Smad1 Signaling and Osteoblastic Differentiation in Murine MC3T3-E1 Cells

    Article • Journal of Bone and Mineral Research, October 2001, Wiley

    Seiji Fukumoto

  155. GH Inhibits Interferon-γ-Induced Signal Transducer and Activator of Transcription-1 Activation and Expression of the Inducible Isoform of Nitric Oxide Synthase in INS-1 Cells

    Article • Endocrinology, September 2001, Endocrine Society

    Seiji Fukumoto

  156. Parathyroid hormone increases the expression level of matrix metalloproteinase-13 in vivo

    Article • Journal of Bone and Mineral Metabolism, July 2001, Springer Science + Business Media

    Seiji Fukumoto

  157. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia

    Article • Proceedings of the National Academy of Sciences, May 2001, Proceedings of the National Academy of Sciences

    Seiji Fukumoto

  158. Effects of 1-year treatment with fluvastatin or pravastatin on bone

    Article • The American Journal of Medicine, May 2001, Elsevier

    Seiji Fukumoto

  159. Fibroblast Growth Factor (FGF)-23 and Hypophosphatemic Rickets/Osteomalacia.

    Article • Endocrine Journal, January 2001, Japan Endocrine Society

    Seiji Fukumoto

  160. Cloning and Characterization of Two Promoters for the Human Calcium-sensing Receptor (CaSR) and Changes of CaSR Expression in Parathyroid Adenomas

    Article • Journal of Biological Chemistry, March 2000, Elsevier

    Seiji Fukumoto

  161. Interactions between Cancer and Bone Marrow Cells Induce Osteoclast Differentiation Factor Expression and Osteoclast-like Cell Formation in Vitro

    Article • Biochemical and Biophysical Research Communications, January 2000, Elsevier

    Seiji Fukumoto

  162. Thiazolidinediones Inhibit Osteoclast-Like Cell Formation and Bone Resorptionin Vitro1

    Article • Endocrinology, November 1999, Endocrine Society

    Seiji Fukumoto

  163. HeterozygousgspMutation Renders Ion Channels of Human Somatotroph Adenoma Cells Unresponsive to Growth Hormone-Releasing Hormone1

    Article • Endocrinology, May 1999, Endocrine Society

    Seiji Fukumoto

  164. Extracellular Matrix-Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Murine Osteoblastic Cellsin Vitro1

    Article • Endocrinology, May 1999, Endocrine Society

    Seiji Fukumoto

  165. An adult patient with severe hypercalcaemia and hypocalciuria due to a novel homozygous inactivating mutation of calcium-sensing receptor

    Article • Clinical Endocrinology, April 1999, Wiley

    Seiji Fukumoto

  166. Stimulation of Osteoclast Formation by 1,25-Dihydroxyvitamin D Requires Its Binding to Vitamin D Receptor (VDR) in Osteoblastic Cells: Studies Using VDR Knockout Mice

    Article • Endocrinology, February 1999, Endocrine Society

    Seiji Fukumoto

  167. Short-Term Treatment with Troglitazone Decreases Bone Turnover in Patients with Type 2 Diabetes Mellitus.

    Article • Endocrine Journal, January 1999, Japan Endocrine Society

    Seiji Fukumoto

  168. A Novel Activating Mutation in Calcium-Sensing Receptor Gene Associated with a Family of Autosomal Dominant Hypocalcemia1

    Article • The Journal of Clinical Endocrinology & Metabolism, January 1999, Endocrine Society

    Seiji Fukumoto

  169. A Novel Activating Mutation in Calcium-Sensing Receptor Gene Associated with a Family of Autosomal Dominant Hypocalcemia

    Article • The Journal of Clinical Endocrinology & Metabolism, January 1999, Endocrine Society

    Seiji Fukumoto

  170. Reduced Expression of Interleukin-11 in Bone Marrow Stromal Cells of Senescence-Accelerated Mice (SAMP6): Relationship to Osteopenia with Enhanced Adipogenesis

    Article • Journal of Bone and Mineral Research, September 1998, Wiley

    Seiji Fukumoto

  171. Cloning and characterization of kidney-specific promoter of human PTH/PTHrP receptor gene: Absence of mutation in patients with pseudohypoparathyroidism type Ib

    Article • Molecular and Cellular Endocrinology, June 1998, Elsevier

    Seiji Fukumoto

  172. Effect of Mechanical Unloading and Reloading on Periosteal Bone Formation and Gene Expression in Tail-Suspended Rapidly Growing Rats

    Article • Bone, May 1998, Elsevier

    Seiji Fukumoto

  173. Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover1

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1997, Endocrine Society

    Seiji Fukumoto

  174. Metabolic Improvement of Poorly Controlled Noninsulin-Dependent Diabetes Mellitus Decreases Bone Turnover

    Article • The Journal of Clinical Endocrinology & Metabolism, September 1997, Endocrine Society

    Seiji Fukumoto

  175. Inhibition of Bone Resorption by Pamidronate Cannot Restore Normal Gain in Cortical Bone Mass and Strength in Tail-Suspended Rapidly Growing Rats

    Article • Journal of Bone and Mineral Research, July 1997, Wiley

    Seiji Fukumoto

  176. A New Synthetic Steroid, Osaterone Acetate (TZP-4238), Increases Cortical Bone Mass and Strength by Enhancing Bone Formation in Ovariectomized Rats

    Article • Journal of Bone and Mineral Research, April 1997, Wiley

    Seiji Fukumoto

  177. Absence of mutations in parathyroid hormone (PTH)/PTH-related protein receptor complementary deoxyribonucleic acid in patients with pseudohypoparathyroidism type Ib

    Article • The Journal of Clinical Endocrinology & Metabolism, July 1996, Endocrine Society

    Seiji Fukumoto

  178. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia

    Article • The Journal of Clinical Endocrinology & Metabolism, February 1996, Endocrine Society

    Seiji Fukumoto

  179. Relationship between actions of transforming growth factor (TGF)-? and cell surface expression of its receptors in clonal osteoblastic cells

    Article • Journal of Cellular Physiology, March 1995, Wiley

    Seiji Fukumoto

  180. Assay of serum pyridinoline: a potential marker for bone resorption

    Article • Clinica Chimica Acta, March 1995, Elsevier

    Seiji Fukumoto

  181. Stimulation of endosteal bone formation by systemic injections of recombinant basic fibroblast growth factor in rats.

    Article • Endocrinology, March 1995, Endocrine Society

    Seiji Fukumoto

  182. Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts

    Article • Biochimica et Biophysica Acta (BBA) - General Subjects, November 1994, Elsevier

    Seiji Fukumoto

  183. Development of a sensitive two-site immunoradiometric assay for parathyroid hormone-related peptide: evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma.

    Article • The Journal of Clinical Endocrinology & Metabolism, November 1994, Endocrine Society

    Seiji Fukumoto

  184. Treatment of malignancy-associated hypercalcemia with YM175, a new bisphosphonate: elevated threshold for parathyroid hormone secretion in hypercalcemic patients.

    Article • The Journal of Clinical Endocrinology & Metabolism, July 1994, Endocrine Society

    Seiji Fukumoto

  185. Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): a paracrine regulator?

    Article • Molecular and Cellular Endocrinology, July 1993, Elsevier

    Seiji Fukumoto

  186. Transforming growth factor β stimulation of parathyroid hormone-related protein (PTHrP): A paracrine regulator?

    Article • Molecular and Cellular Endocrinology, March 1993, Elsevier

    Seiji Fukumoto

  187. Special issue : Calcium.Clinic of bone metabolism abnormality.1.Basic articles.1.Bone and calcium metabolism adjustment hormones.

    Article • Nihon Naika Gakkai Zasshi, January 1993, Japanese Society of Internal Medicine

    Seiji Fukumoto

  188. Plasminogen activator regulation in osteoblasts: Parathyroid hormone inhibition of type-1 plasminogen activator inhibitor and its mRNA

    Article • Journal of Cellular Physiology, August 1992, Wiley

    Seiji Fukumoto

  189. Glucocorticoid regulation of plasminogen activator inhibitor-1 messenger ribonucleic acid and protein in normal and malignant rat osteoblasts.

    Article • Endocrinology, February 1992, Endocrine Society

    Seiji Fukumoto

  190. Pheochromocytoma with Pyrexia and Marked Inflammatory Signs: A Paraneoplastic Syndrome with Possible Relation to Interleukin-6 Production*

    Article • The Journal of Clinical Endocrinology & Metabolism, October 1991, Endocrine Society

    Seiji Fukumoto

  191. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells

    Article • Journal of Cellular Physiology, October 1991, Wiley

    Seiji Fukumoto

  192. Parathyroid Hormone-Related Protein in Adult T-Cell Leukemia-Lymphoma

    Article • Annals of Internal Medicine, September 1989, American College of Physicians

    Seiji Fukumoto

  193. Suppression of Serum 1,25-Dihydroxyvitamin D in Humoral Hypercalcemia of Malignancy Is Caused by Elaboration of a Factor That Inhibits Renal 1,25- Dihydroxyvitamin D3Production*

    Article • Endocrinology, May 1989, Endocrine Society

    Seiji Fukumoto

  194. Effect of 24,25-Dihydroxyvitamin D3on 1,25- Dihydroxyvitamin D3[1,25-(OH)2D3] Metabolism in Vitamin D-Deficient Rats Infused with 1,25-(OH)2D3*

    Article • Endocrinology, January 1989, Endocrine Society

    Seiji Fukumoto

  195. Expression of parathyroid hormone-related protein in a human T cell lymphotrophic virus type I-infected T cell line

    Article • Biochemical and Biophysical Research Communications, August 1988, Elsevier

    Seiji Fukumoto

  196. A hypercalcemic nude rat model that completely mimics human syndrome of humoral hypercalcemia of malignancy

    Article • Calcified Tissue International, August 1988, Springer Science + Business Media

    Seiji Fukumoto

  197. Clinical Evaluation of Calcium Metabolism in Adult T-Cell Leukemia/Lymphoma

    Article • Archives of Internal Medicine, April 1988, American Medical Association (AMA)

    Seiji Fukumoto

  198. Renal Magnesium Wasting in a Patient with Short Bowel Syndrome with Magnesium Deficiency: Effect of 1α-Hydroxyvitamin D3Treatment*

    Article • The Journal of Clinical Endocrinology & Metabolism, December 1987, Endocrine Society

    Seiji Fukumoto

  199. Association of Primary Hyperparathyroidism With Myotonic Dystrophy in Two Patients

    Article • Archives of Internal Medicine, April 1987, American Medical Association (AMA)

    Seiji Fukumoto

  200. Usefulness of Nude Rats in Studies on Characteristics of Human Cancers

    Article • Karger Publishers

    Seiji Fukumoto